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Abstract: Daptomycin (DAP) is a calcium (Ca2+)-dependent FDAapproved antibiotic drug for the treatment of Gram-positive infections.
It possesses a complex pharmacophore hampering derivatization
and/or synthesis of analogs. In order to mimic the Ca2+-binding effect
we used a chemoenzymatic approach to modify the tryptophan (Trp)
residue of DAP and synthesize kinetically characterized and
structurally elucidated regiospecific Trp-modified DAP analogs. We
demonstrated that the modified DAPs are several-folds active than
the parent molecule against antibiotic-susceptible and antibioticresistant Gram-positive bacteria. Strikingly and in contrast to the
parent molecule, the DAP derivatives do not rely on calcium or any
additional elements for activity.
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Introduction
1

Daptomycin/CubicinÒ (DAP, 1, Fig. 1a) is the latest first-in-class
FDA-approved antibiotic drug for the treatment of bacteremia,
endocarditis and complicated skin and skin structure
infections.[1,2] DAP is the only systemically applied membraneactive antibiotic prescribed for the treatment of Gram-positive
bacterial infections.[3–5] Furthermore, DAP has become the last
resort drug for the treatment of challenging infections arising from
antibiotic-resistant Gram-positive bacteria.[6] DAP is an anionic
calcium (Ca2+)-dependent antibiotic, where Ca2+ plays an
essential role in its activity and resistance by decreasing the
required concentration for the 1 membrane insertion 50-fold.[7]
Although not fully understood, the DAP mechanism of action
(MOA) requires Ca2+ binding resulting in neutralization of the DAP
negative charges and in conformational changes involving the
aromatic residues L-tryptophan (Trp1) and kynurenine (Kyn13).
The new conformation exposes 1 hydrophobic regions, increases
its amphipathicity and switches the overall charge of 1 to positive
enhancing DAP oligomerization.[8,9] It is well accepted that the
cationic DAP/Ca2+ complex targets the anionic lipid
phosphatidylglycerol (PG) of the cell membrane leading to either
ion leakage or cell membrane lipid extraction and subsequent
membrane dissipation and cell death.[7] Recently, a MOA showing
that DAP/Ca2+ targets cell wall precursors through the formation
of a tripartite complex with PG has been reported.[10] Thus, we
propose that modifying the DAP Trp1 or Kyn13 residues will
compensate for the Ca2+-induced conformational changes of 1
leading to similar oligomerization and subsequent bacterial cell
death.
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Figure 1. a) Structure of daptomycin (DAP, 1); b) previously reported CdpNPTcatalyzed daptomycin analogs with native donor.

There is a need to develop DAP analogs to overcome its
challenges such as incomplete understanding of the MOA,
inactivity against pneumonia and rising levels of resistance.
However, the structure complexity of 1 has delayed efforts to
develop analogs. DAP is a cyclic lipopeptide composed of 13
nonproteinogenic amino acids carrying a n-decanoic acid chain
attached to the amide of L-Trp1 with multiple chiral centers and
reactive groups (Fig. 1a).[11–13] In fact, the most practical approach
to supply the market demand for 1 remains fermentation of the
producer microorganism, Streptomyces roseosporus and feeding
n-decanoic acid. In spite of these hurdles, efforts from several
groups have led to the development of DAP analogs using
synthetic and combinatorial approaches that suffered frequent
multistep reactions and/or poor regio- and stereospecficity.[14–17]
Data arising from these efforts have generated mostly DAP
derivatives with decreased or abolished antibiotic activities. Yet,
analogs with modifications on the aromatic acids, especially Trp1,
or replacing it with another aromatic amino acid maintained or
increased activity consistent with our hypothesis mentioned
above.[16,18–20] Biocatalysis has gained much interest lately and
has been used to catalyze difficult and uncommon reactions due
to its advantage of regio- and stereospecificity.[21–25] Indole
prenyltransferases (IPTs) are enzymes that utilize naturallyoccurring allyl pyrophosphate donors (OPP) to catalyze the
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transfer of the prenyl group to Trp/indole or indole-containing
acceptor. The significance of IPTs arise from their relaxed
acceptor and donor specificity in addition to their ability to catalyze
C-C bond formation.[26,27] Among these promiscuous IPTs is
CdpNPT, a fungal IPT that has shown broad substrate specificity.
It catalyzes normal (C-1') and/or reverse (C-3') prenylation of Trpcontaining cyclic dipeptides at N-1 or C-3 of the indole,
respectively using native and nonnative OPPs.[28–30] In a previous
study, CdpNPT catalyzed the prenylation of 1 with native OPP
donor, dimethylallyl pyrophosphate (DMAPP) generating two
analogs with normal N-1 and reverse C-3 prenylation that had
improved antimicrobial activities (Fig. 1b).[19] This suggested that
Trp1-modified DAP analogs with improved activities can be
generated by combining CdpNPT with a chemical platform of
noncommercial
nonnative
OPP
with
subsequent
Calkylation/arylation. Since conformational changes associated
with L-Trp1 has been shown to play a key role in 1 activity upon
Ca2+ binding, we hypothesized that the chemoenzymatic
approach proposed will lead to DAPs that are less dependent on
Ca2+. Herein, we report the regiospecific synthesis of three C-6
Trp DAP derivatives using alkyl and aryl OPP as donors and
CdpNPT as a biocatalyst. The chemical structures were
elucidated using HR-ESI-MS and 1- and 2D NMR and their
antimicrobial properties were determined. The analogs displayed
enhanced antimicrobial properties against DAP-susceptible and
DAP-resistant strains with activity that is independent on Ca2+.

Results and Discussion
Our fundamental goal was to synthesize regiospecific and
bioactive Trp1-DAP analogs using CdpNPT enzyme combined
with synthetic nonnative OPPs (Fig. 2a). Thus, we had the E. colicodon optimized cdpNPT gene synthesized (Supplementary Fig.
1). The gene was cloned into a pET28a vector and transformed
into E. coli 5a for sequence verification. The N-His6–CdpNPT
(herein referred to as CdpNPT) was heterologously produced in
E. coli BL21 (DE3) and purified to homogeneity (Supplementary
Fig. 2). In parallel, we synthesized nine alkyl/aryl pyrophosphate
(OPP) donors 2a–2i that cover different chemical space
containing a double bond at the b-position to the diphosphate
group to be accepted by IPTs (Fig. 2b).[27] Established protocols
were followed to generate OPPs by using the corresponding
alkyl/aryl
bromide
4
as
precursors
treated
with
tetrabutylammonium
pyrophosphate
(TBAPP)
at
room
temperature for 2–3 h (Fig. 2b, Supplementary Methods).[31,32] In
the case 4 was not commercially available or cost prohibitive, the
aldehyde was used to generate the desired bromide as in the
case of 2g (Fig. 2b). A series of nonnative donors with allyl (2a,
2b, 2c), propargyl (2f) cyclic alkenes (2g) and aromatic (2h, 2i)
groups were synthesized to demonstrate different functionalities

Figure 2. a) CdpNPT-catalyzed reactions of daptomycin analogs 3x; b)
synthesis of pyrophosphate donors 2, aisolated yield after column
chromatography; c) HPLC chromatogram of reaction mixture containing
daptomycin in Tris 50 mM/CaCl2 10 mM (pH 8.0) incubated for 16 h at 37oC in
the presence of each of 2b, 2g and 2i.

(Fig. 2b). In addition, two analogs were synthesized to mimic the
naturally-occurring donors, geranyl diphosphate (GPP, 2d) and
farnesyl diphosphate (FPP, 2e). The OPP series included donors
with variable chain lengths and two carried terminal alkene (2c)
or alkyne (2f) to facilitate future downstream Diels-Alder or Cumediated click chemistry, respectively. The purified OPPs were
confirmed by HR-ESI-MS, 1H and 31P NMR analyses
(Supplementary Methods, Supplementary Mass Spectra,
Supplementary NMR Spectra).
To assess the potential of CdpNPT to modify DAP, analytical
scale reactions were carried out using 0.4 mM 1, 0.8 mM 2a–2i
and 16 µM CdpNPT in 50 mM Tris buffer (pH 8.0) supplemented
with 10 mM CaCl2 at 37oC for 16 h. Empty pET28a E. coli extract
and subjected to the same purification method was used as
negative control. Analytical scale reactions revealed the formation
of a new product in each of the reactions with (E)-pent-2-en-1-yl
(2b), cyclohex-1-en-1-ylmethyl (2g) and cinnamyl (2i)
diphosphates with conversion percentages of 30, 28 and 15%,
respectively as observed by HPLC and MS (Fig. 2c,
Supplementary Mass Spectra). Furthermore, conversion of <5%
was also shown with the but-2-en-1-yl (2a) and benzyl (2h)
diphosphates as indicated by HPLC and HR-ESI-MS
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(Supplementary Mass Spectra). Thus, CdpNPT was able to
diversify 1 with OPPs attached to moieties with 4–9 carbons

Figure 3. a) Structures of daptomycin analogs 3b, 3g and 3i synthesized enzymatically; b) COSY and HMBC correlations of 3b; c), d) docking models of CdpNPT
(PDB ID 4E0U) using (E)-pent-2-en-1-yl diphosphate (2b) as a donor and (S)-indolylmethylbenzodiazependione (c, Bnz) and daptomycin (d, DAP). Hydrogen bonds
are shown in as black dashes and their corresponding lengths are given in Å; e) proposed mechanism for the formation of 3b.

including alkyl and aromatic groups. All positive reactions
generated one major single product based on chromatograms
(Fig. 2b).
Michaelis-Menten kinetic parameters of CdpNPT for all three
alkyl/aryl OPPs (2b, 2g, 2i) with DAP were determined. The
kinetic parameters, Michaelis constant (Km) as well as turnover

number (kcat) were determined from a nonlinear regression fit of
initial velocities versus the concentration of the alkyl/aryl OPPs by
GraphPad Prism 8.4.3 (Supplementary Table 1). Moreover, we
studied the kinetic parameters of 2b with cyclo-L-Trp-L-Tyr
(Supplementary Fig 3a), a commercially available Trp-containing
dipeptide that structurally mimics the native acceptor S-
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indolylmethylbenzodiazependione (BNZ, Supplementary Fig 3b),
and has shown to act as a substrate for CdpNPT (Supplementary
Figs. 3–6).[33,34] Subsequent determination of CdpNPT steadystate kinetic parameters of 1/2b (Supplementary Fig. 3) and
cyclo(L-Trp-L-Tyr)/2b (Supplementary Fig. 4) showed the catalytic
efficiency to be 0.76 M-1 s-1 and 0.93 M-1 s-1, respectively
(Supplementary Table 1). This shows that CdpNPT can
accommodate both acceptors with the same donor in similar rates,
in spite of the significant size differences. As expected, and
consistent with our HPLC initial screening, the catalytic
efficiencies of CdpNPT with 1/2g (kcat/ Km » 0.72 M-1 s-1)
(Supplementary Fig. 5) was comparable to that of 1/2b. CdpNPT
with DAP/2i had the lowest catalytic efficiency (kcat/ Km » 0.39 M-1
s-1) (Supplementary Fig. 6). This proves that CdpNPT can
accommodate alkyl substrates with moderate carbon chain length
(5–7) in a similar fashion but efficiency decreases when the chain
length of the OPP donor is longer due to potential steric hindrance
in the enzyme active site.
To assess the regiospecificity of CdpNPT with DAP and each of
2b, 2g and 2i, the reactions were scaled up. Reactions in Tris 50
mM (pH 8.0) supplemented with 10 mM CaCl2, containing 1 (0.8–
2 mM), OPP (1.4–2 mM) and 24 µM CdpNPT were prepared and
incubated at 37oC for 16 h. Preparative RP-HPLC purification led
to single modified DAP from each reaction, 3b, 3g and 3i with
isolated yields of 22%, 21% and 15%, respectively
(Supplementary Methods). For structural elucidation purified DAP
analogs were subjected to HR-ESI-MS and 1- and 2D NMR
spectroscopy
to
determine
regiospecificity
(Fig.
3a,
Supplementary Fig. 7). For 3b, the (+)-HR–ESI–MS [M + H]+ m/z
1688.7761 indicated a molecular formula of C77H109N17O26
(Supplementary Mass Spectra). The MS spectrum shows that 3b
has an additional Dm/z = 68 compared to 1 consistent with an
additional −C5H8− group. The 1H, 13C and HSQC NMR
spectroscopic data revealed 77 signals attributable to 5 methyl,
23 methylene, 23 methine, and 26 nonprotonated carbons
(Supplementary Table 2, Supplementary NMR Spectra).
Comparison of 3b 1H and 13C NMR data with 1 1H and 13C NMR
data indicated the presence of additional 1 methyl δC 13.8 (C-5"),
2 methylene δC 38.6 (C-1"), δC 24.9 (C-4") and 2 methine, δC
129.0 (C-2"), δC 132.2 (C-3"). 1H-1H COSY correlations between
H-1" (δH 3.34) /H-2" (δH 5.56), H-3" (δH 5.52) /H-4" (δH 1.99) and
H-4"/H-5" (δH 0.94) as well as the 1H-13C HMBC correlations (H5" to C-3", H-4" to C-3"/C-2" and H-1" to C-3"/C-2") deduced the
presence of a pent-2-en-1-yl group indicating the presence of a
normal (C-1") not reverse (C-3") reaction (Fig. 3b, Supplementary
Fig. 8). All of the remaining COSY and HMBC correlations of 3b
were in full agreement with that of 1 except for the indole moiety
(Supplementary Table 2, Supplementary NMR Data). The COSY
correlations between H-4 (δH 7.47)/H-5 (δH 6.79) and H-1 (δH
10.62)/H-2 (δH 7.06) as well as the HMBC correlations between
H-5 to C-1"/C-7 (δC 110.5), H-7 (δH 7.07) to C-1"/C-5 (δC 119.3),
H-2" to C-6 (δC 133.2) and H-1" to C-5/C-7 determined the
regiospecificity to be at the C-6 of DAP indole. The configurational
assignments of 2"-E were deduced by calculating the coupling
constants of H-2" (dt, J = 15.2, 6.0 Hz). Thus, the structure of 3b
was established to be 6-C-((E)-pent-2-en-1-yl)-L-Trp1-daptomycin.
For structure elucidation of 3g and 3i, the HR–ESI–MS [M + H]+
m/z 1714.7959 and m/z 1736.7820 indicated the molecular
formulas of C79H111N17O26 and C81H110N17O26, respectively. 1- and
2D NMR established 3g and 3i to be 6-C-(cyclohex-1-en-1ylmethyl)-L-Trp1-daptomycin
and
6-C-(cinnamyl)-L-Trp1-

daptomycin, respectively (for full structure elucidation of 3g and
3i, see Supplementary Methods, Supplementary Fig. 9,
Supplementary Fig. 10, Supplementary Mass Spectra and
Supplementary NMR Spectra). This highlights the significance of
this chemoenzymatic approach in developing regiospecific DAP
analogs at a challenging position as the indole C-6. During the
preparation of this manuscript, Scull et al. reported the generation
of DAP analogs 3g and 3i using CdpNPT.[35] However, our
kinetically-characterized reactions led to regiospecific DAP
products in contrast to the reported work which could be attributed
to the increase in enzyme promiscuity under different
conditions.[36] Noteworthy, comparing the analogs synthesized
herein (C-6) with those generated from previous efforts shows
that changing the donors used with DAP/CdpNPT system leads
to variation in the alkylation/arylation positions of 1.[19,35]
We sought to investigate the structural basis of DAP docking into
the binding pocket of CdpNPT and determine the basis of
regiospecific DAP analogs produced in this study and
discrepancy when compared to native acceptor. CdpNPT
catalyzes the reverse prenylation of BNZ and cyclo-L-Trp-L-Tyr at
the C-3 using DMAPP (native donor) and 2b respectively, which
rearranges to provide the normal prenyl at N-1.[30,32,34,37] Indeed,
CdpNPT catalyzed the nonnative DAP prenylation at the N-1 and
C-3 positions when coupled with DMAPP (Fig. 1b).[19] Since the
3D-structure of a DAP-CdpNPT-bound complex is not available,
we used molecular modeling of the ternary CdpNPT 3D-structure
cocrystallized with the native acceptor BNZ and a donor mimic,
thiolodiphosphate (PDB ID 4E0U).[37] Thus, ICM Molsoft was used
to virtually dock 2b with each of BNZ (Fig. 3c) and DAP (Fig. 3d).
The binding pocket was identified and the hits with the lowest
score indicated less energy and higher stability. Our models show
that the donor 2b is anchored in the binding pocket by
electrostatic interaction between the anionic 2b diphosphate and
the cationic residues (Arg129, Lys219, Arg284, Lys286, Lys364)
in addition to a hydrogen bond with Tyr431.[37] Previous reports
support that the formed carbocation, generated from the loss of
the diphosphate, is stabilized by the tyrosine shield (Tyr 221,
Tyr288, Tyr366, Tyr431) via p-cation interactions.[26,37] It is
expected that 2g will exist in the chair form inside the cavity taking
a comparable size as 2b which could explain the similar catalytic
efficiencies. Compared to 2g, 2h produced less yield which could
be explained by flattening of the aromatic ring and subsequent
steric hindrance. Replacing the methyl group in 2b with phenyl in
2i led to decrease in the enzyme kinetics showing the effect of
steric hindrance on the catalytic efficiency. The cavity surrounding
the donor 2b is spacious enough to allow for slightly larger chain
such as the cinnamyl group in 2i. The residue Met349 seems to
act as the gatekeeper preventing CdpNPT from accepting larger
donors. Indeed, engineering of M349G has provided a biocatalyst
that can accommodate GPP (2d) when combined with a simple
dipeptide as acceptor.[33] This implies that using the engineered
CdpNPT_M349G instead of wild-type enzyme with 1 is a
promising approach to diversify DAP when coupled with bulkier
donors.
The indole-moiety of the acceptor is positioned between the alkyl
chain of OPP and Glu116 whose role is to act as a nucleophile to
activate the indole ring (Fig. 3c, Fig. 3d). In our model, the NH and
C-3 of the BNZ are distanced at 2.96 and 3.89 Å from the Glu116
acidic and the C-3 alkyl side chain of 2b, respectively (Fig. 3c).
On the other hand, 1 fits itself deep onto the spacious binding
pocket of CdpNPT where the indole faces downward parallel to
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hydrogen bond with polar residues including Cys107, Thr108,
Thr203, Asp210 and Glu220. Hence, the proposed mechanism of
the formation of these analogs is initiated by the release of the
diphosphate from the donor (Fig. 3e). Subsequent Friedel-Crafts
aromatic substitution at the C-6 position of the indole leads to the
formation of an arenium intermediate followed by deprotonation
to restore aromaticity and produce the C-6-substituted DAP
analogs.[26,27]

Table 1. MIC values of daptomycins DAP, 3b, 3g, and 3i, in the presence of 50 mg L-1 calcium and 10 mM EDTA, respectively. NG, no growth; values in μM (mg
L-1). Daptomycin-resistant strains are highlighted in green. The most well established daptomycin-resistant mechanisms include DAP-repulsion or diversion away
from the bacterial division septum. This involves the reduction of the anionic PG content by downregulating the PG synthase (pgsA), lysinylation of PG via MprF,
increase in the cardiolipin synthesis on the expense of PG, shedding of the PG lipids or D-alanylation of teichoic acids.[3,6,38]
Ca2+

EDTA

Compound
Type

DAP

3b

3g

3i

DAP

3b

3g

3i

Strain
E. faecalis B-537

3.60 (5.8)

0.25 (0.4)

0.38 (0.6)

0.45 (0.8)

>72 (>116)

1.00 (1.7)

0.75 (1.3)

0.90 (1.6)

DAP-susc. E. faecalis S613

3.60 (5.8)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

36 (58)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

18 (29)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

>72 (>116)

4.00 (6.8)

3.10 (5.3)

1.80 (3.1)

E. faecium TX1330

9.0 (14.5)

1.00 (1.7)

0.75 (1.3)

0.90 (1.6)

>72 (>116)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

E. faecium UAA714

9.0 (14.5)

1.00 (1.7)

0.75 (1.3)

0.90 (1.6)

72 (116)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

S. aureus ATCC 6538

1.8 (2.9)

0.50 (0.85)

0.75 (1.3)

0.90 (1.6)

36 (58)

1.00 (1.7)

0.75 (1.3)

0.90 (1.6)

Methicillin res. S. aureus

1.8 (2.9)

0.50 (0.85)

0.75 (1.3)

0.90 (1.6)

36 (58)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

Vancomycin res. S. aureus

1.8 (2.9)

0.50 (0.85)

0.75 (1.3)

0.45 (0.8)

72 (116)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

S. aureus SA-1199B
S. aureus SAUSA3001713

1.8 (2.9)

0.50 (0.85)

0.38 (0.6)

0.45 (0.8)

72 (116)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

9 (14.5)

0.5 (0.85)

0.75 (1.3)

0.90 (1.6)

>72 (>116)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

S. aureus SAUSA3001715

9 (14.5)

0.5 (0.85)

0.75 (1.3)

0.90 (1.6)

>72 (>116)

2.00 (3.4)

1.50 (2.6)

1.80 (3.1)

Micrococcus luteus B-287

0.22 (0.4)

0.06 (0.1)

0.19 (0.33)

0.23 (0.4)

3.60 (5.8)

0.25 (0.4)

0.19 (0.3)

0.23 (0.4)

Bacillus subtilis B-14596

1.80 (2.9)

0.12 (0.2)

0.09 (0.15)

0.23 (0.4)

72 (116)

0.50 (0.9)

0.38 (0.6)

0.45 (0.8)

Mycobacterium aurum

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

NG

NG

NG

NG

Mycobacterium smegmatis

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

NG

NG

NG

NG

Enterobacter cloacae

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

Salmonella enterica

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

Escherichia coli

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

Saccharomyces cerevisiae

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

>36 (>58)

>40 (>67)

>31 (>53)

>18 (>31)

DAP-res. E. faecalis R712

Gram
positive

Gram
negative
Fungus

Prenylated DAP analogs modified with native donor DMAPP have
shown improved antimicrobial properties when compared to the
parent 1.[19] Thus, we screened our purified analogs with different
bacterial and fungal strains (Table 1). No activity was detected in
any of the modified analogs against the Gram-negative bacteria
Enterobacter cloacae UCI 3, Salmonella enterica, or Escherichia
coli or the fungus Saccharomyces cerevisiae (Table 1).
Furthermore, the analogs showed no increase in cytotoxicity
against HEK293 eukaryotic cells when compared to 1. Our
preliminary screening assays using DAP and 3b were tested
against a small panel of Gram-positive bacteria in the presence of
50 mg L-1 Ca2+ as recommended for antimicrobial screening of
lipopeptides in general and DAP in specific (Supplementary Table
4).[39,40] Analog 3b showed 4–33 fold MIC improvement when
compared to 1. In order to assess the reliance of generated DAPs
on Ca2+, we repeated the screening in the absence of any added
ions. As expected, we found that DAP MIC deteriorated by 2–30
fold. In fact, the MIC even increased several folds in the absence
of the chelating agent EDTA which is expected as Ca2+ is
essential for 1 activity. Strikingly, 3b was minimally affected by the
absence of Ca2+ (Supplementary Table 4). In order to ensure that
no undetected impurities are present due to purification process
which might contribute to activity, we used unreacted 1 that was

incubated in enzymatic reactions with CdpNPT and 2b in the
presence of buffer and was purified via reversed-phase HPLC as
a positive control. We obtained comparable results showing that
at least one of our enzymatically-synthesized compounds, not
DAP, is active in the absence of Ca2+. To confirm our results and
to test a broader aspect on antimicrobial activities, we subjected
our three Trp1-modified analogs, in addition to 1 to a final HPLC
run to get rid of any residual acid from the initial purification that
might contribute to activity, as indicated by lack of peaks
corresponding to formic acid or trifluoro acetic acid in our 1H and
13
C NMR spectra. The concentrations of the tested materials were
then adjusted by measuring absorbance using Beer-Lambert law.
We then repeated the antimicrobial screening using all purified
analogs subjected to similar conditions to a wider panel of 19
microorganisms of different antibiotic-resistant bacteria including
the three DAP-resistant strains E. faecalis R712, S. aureus
SAUSA300_1713 and S. aureus SAUSA300_1715 (Table 1). In
the presence of 50 mg L-1 Ca2+, analogs 3b, 3g and 3i possessed
1.5–20 fold improved MIC when compared to 1 against Grampositive strains including methicillin, vancomycin and
ciprofloxacin-resistant strains. The three analogs possessed
comparable MICs to each other with 3b being slightly better
(Table 1). DAP forms a cationic complex with Ca2+ (Fig. 4a) that
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the attached n-decanoic lipid chain. DAP docks such that it is
positioned at 3.20 Å and 3.42 Å from the Glu116 acidic side chain
and C-1 of the 2b alkyl side chain, respectively with 300o
clockwise rotation compared to the BNZ indole (Fig. 3d). This
orientation allows for access of the OPP C-1" to attack the C-6 of
the DAP Trp. DAP seem to form hydrophobic interactions with the
nonpolar regions of 1 with the residues Leu109, Ala131, Val201,
Val206, Val207, Ala208, Phe223, Phe272, Trp419 and form
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4d).[7] Diversion is an alternative mechanism which involves
anionic membrane lipids acting as DAP sink holes that migrate
away from the vital cell division septum. Our Ca2+-independent
Trp-modified DAP seem to overcome resistance by avoiding the
formation of cationic complex and thus circumvent DAP-repulsion
or diversion (Fig. 4d). It is tempting to assume that the biocatalytic
modification of the DAP Trp1 with alkyl or aromatic groups
changes the conformation of 1 in a similar fashion when bound to
Ca2+ leading to the enhanced insertion of 1 into the cell membrane
(Fig. 4c). An alternative explanation where the Trp-modification of
1 led to increase in hydrophobicity and facilitated oligomerization
has been suggested but would not explain the impressing activity
against DAP-resistant strains and the Ca2+ independency.[16]
Taken together, these data suggest that the generated 3b, 3g and
3i analogs act as drug leads with a new MOA that is yet to be
explored.

causes conformational changes involving Trp1 and ion charge
variations. This allows 1 to bind the anionic lipid membranes,
possibly at the bacterial division septum with subsequent
membrane dissipation (Fig. 4c).[7,8] Interestingly, while DAPresistant E. faecalis R712 was 5-fold more tolerant to 1 than DAPsusceptible E. faecalis S613, the enzymatically-modified analogs
(Fig. 4b) were equally active against both strains highlighting the
importance of Trp1-modification to combat resistance (Table 1).
Similar results were seen with the two DAP-resistant S. aureus
strains (Table 1). In the absence of Ca2+ via the addition of EDTA
as a chelating agent, 1 activity was deteriorated or abolished
(Table 1). On the contrary, the 3b, 3g and 3i showed no or
minimal effect on MIC suggesting that these analogs avoid the
MOA used by DAP/Ca2+ complex. DAP-resistance has been
postulated to occur via repulsion where the bacterium
overproduces cationic lysyl-PG on the expense of anionic PG (Fig.

Figure 4. a) Formation of DAP/Ca2+ complex; b) formation of Trp1-modified daptomycin analogs (3b, 3g and 3i); c) proposed mechanisms of actions for DAP/Ca2+
and 3b, 3g and 3i rely on binding to the anionic lipids located at the bacterial division septum leading to DAP or DAP analogs oligomerization and subsequent
membrane dissipation; d) Proposed mechanism for 3b, 3g and 3i to overcome DAP-resistance. Bacteria develop DAP-resistance by decreasing the anionic lipid
content or via diversion od DAP to other areas away from the division septum. Trp-modified DAP analogs are capable of binding to the neutral or cationic lipids
causing bacterial growth inhibition. OPP, alkyl and aryl pyrophosphate; IPT, indole pyrophosphate; ML, membrane lipid; AL, anionic lipids such as
phosphatidylglycerol; LPG, lysylphosphatidylglycerol; DAP, daptomycin.

Ca2+-dependent antibiotic lipopeptides, which is unprecedented.
Yet, further studies are needed to explain how the enzymatically
synthesized DAP derivatives inhibit Gram positive bacteria in the
absence of Ca2+. The current study opens the door for drug
properties enhancement for cationic antimicrobial peptides that
works through the same MOA of DAP/Ca2+ complex. Furthermore,
this work provides a proof-of-concept for the regiospecific
diversification and differential alkylation/arylation of 1 and other
Trp-containing peptides for drug discovery and other
synthetic/tagging applications using wild-type and/or engineered
IPTs.

Conclusion
We synthesized a library of diverse alkyl and aryl OPPs (2a–2i)
and coupled them with a promiscuous IPT, CdpNPT to generate
regiospecific C-6 Trp1-modified DAP derivatives via C-C bond
formation. The kinetically-characterized compounds were scaled
up, purifed and the structures were determined using MS and 1and 2D NMR spectroscopy. The DAP analogs 3b, 3g and 3i were
found to be several folds active than the parent 1 against different
antibiotic-resistant Gram-positive bacteria with no apparent effect
on cytotoxicity. Moreover, these analogs will feed into the DAPanalogs pipeline to fully reveal the 1-MOA as well as the DAPresistance mechanism. Most importantly, 3b, 3g and 3i were
active in the absence of Ca2+, an essential ion for DAP and other
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.
Daptomycin relies on calcium as an essential element for its strong antibiotic activity. Herein, we use a chemoenzymatic approach to
synthesize regiospecific daptomycin derivatives that are independent on calcium and are more active than the parent daptomycin
against daptomycin-susceptible and daptomycin-resistant Gram-positive bacteria.
Researcher Twitter username: SherifElshahawi

8

This article is protected by copyright. All rights reserved.

Accepted Manuscript

Entry for the Table of Contents

